home All News open_in_new Full Article

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the […]


today 1 week ago attach_file Sport

attach_file Sport
attach_file Society
attach_file Sport
attach_file Other
attach_file Other
attach_file Other


ID: 1180851240
Add Watch Country

arrow_drop_down